We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Mirus Bio Announces Genetic Immunization Method to Produce Antibodies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mirus Bio Announces Genetic Immunization Method to Produce Antibodies"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Scientists at Mirus Bio Corporation have developed a genetic immunization technique for making high-quality antibodies. This proprietary process is described in the February issue of the journal BioTechniques.

It involves a method of intravenously injecting DNA into animals, whose immune systems respond by producing antibodies that can be harvested for subsequent use.

Conventional methods of generating antibodies require the slow process of identifying, isolating, and purifying the protein which serves as the target antigen.

The resulting protein is then injected into animals to elicit an antibody response, after which the antibodies are harvested and used for their intended purpose.

However, due to the processes employed, such purified proteins may not be identical to the natural antigenic protein, and therefore may not be as potent at eliciting an immune response.

The technique developed at Mirus Bio is designed to bypass these hurdles and enables research animals to naturally produce antigenic proteins that elicit a potent antibody response.

"This represents yet another breakthrough application of our nucleic acid delivery portfolio," notes Jon A. Wolff, M.D., Mirus Bio's Chief Scientific Officer.

This research tool is available for licensing for those who wish to use it within the biotechnology and pharmaceutical industry, either for internal research or as part of a commercial antibody production service.